Reuters(@Reuters):GLP-1 drugs like Novo Nordisk's Ozempic and Wegovy rank among the biggest medical breakthroughs in years, owing to their efficacy in treating obesity and type 2 diabetes, and reducing the risk of heart disease. Some 10 million Americans used them last year, a figure that could grow to 25 million by 2030, according to JPMorgan research. Their side effects, though, have caused many to turn to loosely regulated dietary supplements

Reuters

@Reuters

Top and breaking news, pictures and videos from Reuters. For breaking business news, follow @ReutersBiz. Our daily podcast is here:

加入 March 2007

1.2K 正在關注 26.4M 粉絲

Reuters@Reuters

2026.10.20 07:50

GLP-1 drugs like Novo Nordisk's Ozempic and Wegovy rank among the biggest medical breakthroughs in years, owing to their efficacy in treating obesity and type 2 diabetes, and reducing the risk of heart disease. Some 10 million Americans used them last year, a figure that could grow to 25 million by 2030, according to JPMorgan research. Their side effects, though, have caused many to turn to loosely regulated dietary supplements